PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.76
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
1733.11
P/S above 1.5x CRVO's 17.38. Michael Burry would check for mean reversion risks.
3.86
P/B 50-75% of CRVO's 5.87. Bruce Berkowitz would examine if asset composition explains the gap.
-18.74
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-18.74
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
3.86
Fair value ratio 50-75% of CRVO's 5.87. Bruce Berkowitz would examine if business quality explains the gap.
-6.64%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-5.34%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.